Table 2.
Timing of associations between medications and ICI response
| Cancer Type | Drug Type | Timing Window (days) | Sig PFS | Sig OS | N Drug Users | N Total | PFS HR | OS HR | Uni vs Multi Variate | Controlled Covariates | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| This study | Melanoma | ABx | +/− 28 | Yes | 48 | 185 | 1.66 | Multi | CS, ECOG, BMI, G, A, CG | ||
| [14] | Melanoma | ABx | (−30)-0 | Yes | No | 10 | 74 | 0.32 | 0.52 | Multi (only for PFS) | A, E, G, LT, IR, Serum levels of lactate dehydrogenase (LDH), BRAF status |
| This study | NSCLC | ABx | +/− 28 | No | 64 | 152 | 0.81 | Multi | CS, ECOG, BMI, G, A, CG | ||
| [13] | NSCLC | ABx | +/− 28 | Yes | Yes | 20 | 109 | 0.29 | 0.35 | Multi | A, G, S, E, His, Mut, LT, IR, CT |
| [22] | NSCLC | ABx | (−30)-0 | Yes | Yes | 48 | 239 | 1.3 | 2.5 | Multi | A, His, S, PR, E, C, Hos |
| [13] | NSCLC | ABx | (−60)-0 | Yes | Yes | 20 | 109 | 0.29 | 0.35 | Multi | A, G, His, S, E, LT, C, IR Mutation, ABx, PPIs |
| [22] | NSCLC | ABx | (− 60)-0 | No | Yes | 68 | 239 | 1.2 | 2 | Multi | A, His, S, PR, E, C, Hos |
| [2] | NSCLC | ABx | (−84)-0 | No | Yes | 37 | 140 | 2.31 | Multi | A, G, His, S, PR, E, MS | |
| [2] | RCC | ABx | (−30)-0 | Yes | Yes | 16 | 121 | 2.2 | 2.1 | Multi | A, TB, R |
| [22] | RCC | ABx | (−60)-0 | Yes | No | 22 | 121 | 2.3 | 1.9 | Multi | A, TB, R |
| [2] | RCC | ABx | (−84)-0 | Yes | No | 20 | 67 | 2.16 | Multi | A, G, R, TB | |
| [2] | UC | ABx | (−84)-0 | No | No | 12 | 42 | 1.97 | Multi | Hemoglobin levels, KPS, Liver M | |
| [49] | Several | Abx | (−30)-0 | Yes | 29 | 167 | 7.4 | Uni | |||
| [49] | Several | Abx | 0+ | No | 68 | 128 | 0.9 | Uni | |||
| [49] | Several | Abx | (−30)-- | Yes | 29 | 167 | 8.2 | Multi | Cancer, E, CG, TB, A, CS | ||
| This study | Melanoma | CS | +/− 28 | Yes | 66 | 185 | 1.57 | Multi | ABx, ECOG, BMI, G, A, CG | ||
| [48] | NSCLC | CS (Cancer-related) | +/− 1 | No | Yes | 66 | 650 | 1.4 | 1.6 | Multi | A, G, S, His, LT, IR, E, Mut, Brain M, PD-L1 TPS, %, Median TMB |
| [48] | NSCLC | CS (Cancer-unrelated) | +/− 1 | No | No | 27 | 650 | 0.62 | 0.91 | Multi | A, G, S, His, LT, IR, E, Mut, Brain M, PD-L1 TPS, %, Median TB |
| [21] | NSCLC | CS | 0 + 28 | Yes | Yes | 35 | 151 | 1.88 | 2.38 | Multi | A, G, S, His, MS, E, LT, IR, Brain M Bone M, Liver M, PD-L1 expression, CS |
| This study | NSCLC | CS | +/− 28 | Yes | 67 | 152 | 1.85 | Multi | ABx, E, BMI, G, A, CG | ||
| [9] | NSCLC | CS | (−30)-0 | Yes | Yes | 90 | 640 | 1.3 | 1.7 | Multi | S, E, Brain M |
| [13] | NSCLC | PPIs | +/− 28 | No | No | 40 | 109 | 1.1 | 1.47 | Uni | |
| [2] | NSCLC | PPIs | (−84)-0 | No | No | 35 | 140 | Uni | |||
| [2] | RCC | PPIs | (−84)-0 | No | No | 20 | 67 | Uni | |||
| [2] | UC | PPIs | −84 | No | No | 7 | 42 |
Abbreviations: A Age, G Gender, R IMDC Risk, TB Tumor Burden, His Histology, S Smoking History, PR Number of Prior Regimens, E ECOG Performance Status, C Clinical Trial, Hos Hospitalization, MS Number of Metastatic Sites, LT Line of Therapy, IR ICI Regimen, CS Corticosteroids, ABx Antibiotics, CG Cancer Stage, M Metastases, Mut Mutation